a new future

Will be a good read for all if you can get it, I like the "The authors have purchased shares in Tissue Therapies Ltd" disclaimer in the bottom link, thanks Zee:) It was only released recently and may have helped a bit with the recent rise in sp also, this all seems rather bully for us.

2 links:

http://www.liebertpub.com/products/product.aspx?pid=280

An Authoritative Desktop Reference For All Wound Care Professionals
Wound Healing Society Yearbook Publication

Volume 1 Now Published
Click tabs above for Table of Contents and Sample Chapters
Read Dr. Sen's Preface!

Editorial Board

Volume 2 publishing 2011 Outline
Call for Manuscripts - Author Instructions
Volume 2 - Sample Chapter
SUBMIT Volume 2 Manuscripts to: http://mc.manuscriptcentral.com/whsyb

Successful advancement of the wound healing discipline depends on effective integration of scientific discoveries and wound care practices. The science of wound healing is heavily interdisciplinary in nature.
Even for accomplished scientists, staying abreast with the latest developments in the science of wound care is a daunting task. For wound care professionals it is almost impossible to closely monitor relevant scientific developments in such a diverse atmosphere. Thus, there is a fast growing gap between the frontiers of science and the quality of education and patient care.
The first in an annual book series, Advances in Wound Care is a compilation of the latest developments and advances in the field and will serve as a comprehensive, authoritative reference to fulfill the need in the literature. This book series will provide a simple yet Authoritative Desktop Reference for wound care professionals as well as graduate students who may not have sufficient exposure to aspects of wound healing other than their specific area of study. Seminal basic science discoveries will be highlighted with the intent to explore the future potential in wound care. A new volume in this series will be released at the annual conference of the Wound Healing Society

------------------------------------------------------------------------------------------------------------------------

http://eprints.qut.edu.au/33705/

A new future for growth factor complexes as wound therapies?

Deposited On: 15 Dec 2010 10:57
Last Modified: 18 Dec 2010 00:55

Leavesley, David & Upton, Zee (2010) A new future for growth factor complexes as wound therapies? In: Sen, Chandon (Ed) Advances in Wound Care. Wound Healing Society Yearbook Series, 2. Mary Ann Liebert, Inc., New Rochelle, New York, pp. 155-160. (In Press)

Background, Topical administration of growth factors (GFs) has displayed some potential in wound healing, but variable efficacy, high doses and costs have hampered their implementation. Moreover, this approach ignores the fact that wound repair is driven by interactions between multiple GFs and extracellular matrix (ECM) proteins. The Problem, Deep dermal partial thickness burn (DDPTB) injuries are the most common burn presentation to pediatric hospitals and also represent the most difficult burn injury to manage clinically. DDPTB often repair with a hypertrophic scar. Wounds that close rapidly exhibit reduced scarring. Thus treatments that shorten the time taken to close DDTPB�s may coincidently reduce scarring. Basic/Clinical Science Advances, We have observed that multi-protein complexes comprised of IGF and IGF-binding proteins bound to the ECM protein vitronectin (VN) significantly enhance cellular functions relevant to wound repair in human skin keratinocytes. These responses require activation of both the IGF-1R and the VN-binding αv integrins. We have recently evaluated the wound healing potential of these GF:VN complexes in a porcine model of DDTPB injury. Clinical Care Relevance, This pilot study demonstrates that GF:VN complexes hold promise as a wound healing therapy. Enhanced healing responses were observed after treatment with nanogram doses of the GF:VN complexes in vitro and in vivo. Critically healing was achieved using substantially less GF than studies in which GFs alone have been used. Conclusion These data suggest that coupling GFs to ECM proteins, such as VN, may ultimately prove to be an improved technique for the delivery of novel GF-based wound therapies.

The authors wish to acknowledge Carolyn Hyde, Sarah Tilley, Brett Hollier, Christopher Towne, Jennifer Kricker, Leila Cuttle, Anthony Noble, Margit Kempf, Gemma Topping, Jos Malda, Yan Xie, Julie Mill, Damien G. Harkin, Olena Kravchuk, and Roy M. Kimble for their invaluable contributions to this research. The work described in this work has been funded by awards from the National Health and Medical Research Council (NHMRC) of Australia, Australian Research Council (ARC), Juvenile Diabetes Research Trust (Australia), Tissue Therapies Ltd and Queensland Smart State Fellowship (ZU). The authors have purchased shares in Tissue Therapies Ltd., the Australian biotechnology company spun out from the Queensland University of Technology (patent holder) to commercialise this technology. The authors provide consultant scientific services to Tissue Therapies Ltd. This work is solely that of the listed authors.